Join our daily newsletter At The Bell to receive exclusive market insights
Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with Tessara Therapeutics – which showed its lead drug NUZ-001 produced several positive effects on the brain.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The study analysed the effects of the drug candidate on Tessara’s RealBrain 3D human tissues model – a 3D model of the brain – and found both NUZ-001 and NUZ-001 Sulfone (which was also included in this particular study) were safe when applied to a healthy human brain.
The two tested drugs also reportedly provided neuroprotective properties against neurotoxic insult (damage to the brain and nervous system caused by toxic substances) and encouraged the health of brain tissues.
Additionally, they may potentially boost neuronal branching, enabling neuroplasticity.
Tessara’s Principal Scientist Dr Mark Greenough will be presenting the results of the study at the AD/PD 2025 Advances in Sciences & Therapy Conference, with AD/PD being the most prestigious international conference addressing Alzheimer’s and Parkinson’s diseases. The conference will be held in Vienna.
Further research is being done to explore how the NUZ-001 Tessara’s ADBrain model might have therapeutic benefits for sporadic Alzheimer’s disease
Results on that front are expected this quarter, the company has today confirmed.
“These findings indicate short-term treatment with NUZ-001 and NUZ-001 Sulfone maintains an excellent safety profile in Tessara’s RealBrain micro-tissues,” Tessara’s managing director and CEO Dr Christos Papadimitrio said.
In addition, the compounds appear to offer neuroprotective effects against ferroptosis
and encourage neural branching, potentially boosting plasticity by enabling neurons to form additional connections.
“While further research is needed to clarify the mechanisms responsible… data suggests longer-term treatment may enhance network density and plasticity.”
More market news
Never-ending: And just like that, Trump’s tariffs are back causing more market chaos
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
“In humans, this could translate into tangible benefits in cognition, learning, memory, or resilience to neurodegenerative processes involved in diseases such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis.”
Neurizon shares have been trading at 13 cents this morning.
Join the discussion: See what HotCopper users are saying about Neurizon and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
